The Ebola Virus Glycoprotein and HIV-1 Vpu Employ Different Strategies to Counteract the Antiviral Factor Tetherin

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2011 Oct 12

PMID 21987761

Citations 46

Authors

Annika Kuhl

Carina Banning

Andrea Marzi

Jorg Votteler

Imke Steffen

Stephanie Bertram

Ilona Glowacka

Andreas Konrad

Michael Sturzl

Ju-Tao Guo

Ulrich Schubert

Heinz Feldmann

Georg Behrens

Michael Schindler

Stefan Pohlmann

Affiliations

Soon will be listed here.

Abstract

The antiviral protein tetherin/BST2/CD317/HM1.24 restricts cellular egress of human immunodeficiency virus (HIV) and of particles mimicking the Ebola virus (EBOV), a hemorrhagic fever virus. The HIV-1 viral protein U (Vpu) and the EBOV-glycoprotein (EBOV-GP) both inhibit tetherin. Here, we compared tetherin counteraction by EBOV-GP and Vpu. We found that EBOV-GP but not Vpu counteracted tetherin from different primate species, indicating that EBOV-GP and Vpu target tetherin differentially. Tetherin interacted with the GP2 subunit of EBOV-GP, which might encode the determinants for tetherin counteraction. Vpu reduced cell surface expression of tetherin while EBOV-GP did not, suggesting that both proteins employ different mechanisms to counteract tetherin. Finally, Marburg virus (MARV)-GP also inhibited tetherin and downregulated tetherin in a cell type-dependent fashion, indicating that tetherin antagonism depends on the cellular source of tetherin. Collectively, our results indicate that EBOV-GP counteracts tetherin by a novel mechanism and that tetherin inhibition is conserved between EBOV-GP and MARV-GP.

Citing Articles

Blocking of ebolavirus spread through intercellular connections by an MPER-specific antibody depends on BST2/tetherin.

Santos R, Ilinykh P, Pietzsch C, Ronk A, Huang K, Kuzmina N Cell Rep. 2023; 42(10):113254.

PMID: 37858466 PMC: 10664807. DOI: 10.1016/j.celrep.2023.113254.

The Feline Immunodeficiency Virus Envelope Signal Peptide Is a Tetherin Antagonizing Protein.

Morrison J, Poeschla E mBio. 2023; 14(2):e0016123.

PMID: 36927083 PMC: 10128041. DOI: 10.1128/mbio.00161-23.

Structural and Functional Aspects of Ebola Virus Proteins.

Jain S, Martynova E, Rizvanov A, Khaiboullina S, Baranwal M Pathogens. 2021; 10(10).

PMID: 34684279 PMC: 8538763. DOI: 10.3390/pathogens10101330.

Interferon-Induced HERC5 Inhibits Ebola Virus Particle Production and Is Antagonized by Ebola Glycoprotein.

Paparisto E, Hunt N, Labach D, Coleman M, Di Gravio E, Dodge M Cells. 2021; 10(9).

PMID: 34572049 PMC: 8472148. DOI: 10.3390/cells10092399.

Immunological Perspective for Ebola Virus Infection and Various Treatment Measures Taken to Fight the Disease.

Jain S, Khaiboullina S, Baranwal M Pathogens. 2020; 9(10).

PMID: 33080902 PMC: 7603231. DOI: 10.3390/pathogens9100850.

References

McNatt M, Zang T, Hatziioannou T, Bartlett M, Fofana I, Johnson W . Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog. 2009; 5(2):e1000300. PMC: 2633611. DOI: 10.1371/journal.ppat.1000300. View

Marzi A, Akhavan A, Simmons G, Gramberg T, Hofmann H, Bates P . The signal peptide of the ebolavirus glycoprotein influences interaction with the cellular lectins DC-SIGN and DC-SIGNR. J Virol. 2006; 80(13):6305-17. PMC: 1488929. DOI: 10.1128/JVI.02545-05. View

Goffinet C, Homann S, Ambiel I, Tibroni N, Rupp D, Keppler O . Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu. J Virol. 2010; 84(8):4089-94. PMC: 2849503. DOI: 10.1128/JVI.01549-09. View

Leroy E, Rouquet P, Formenty P, Souquiere S, Kilbourne A, Froment J . Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science. 2004; 303(5656):387-90. DOI: 10.1126/science.1092528. View

Kaletsky R, Francica J, Agrawal-Gamse C, Bates P . Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci U S A. 2009; 106(8):2886-91. PMC: 2650360. DOI: 10.1073/pnas.0811014106. View

Gao F, Li Y, Decker J, Peyerl F, Bibollet-Ruche F, Rodenburg C . Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: in vitro expression and immune responses in DNA-vaccinated mice. AIDS Res Hum Retroviruses. 2003; 19(9):817-23. DOI: 10.1089/088922203769232610. View

Sauter D, Specht A, Kirchhoff F . Tetherin: holding on and letting go. Cell. 2010; 141(3):392-8. DOI: 10.1016/j.cell.2010.04.022. View

Bavari S, Bosio C, Wiegand E, Ruthel G, Will A, Geisbert T . Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med. 2002; 195(5):593-602. PMC: 2193767. DOI: 10.1084/jem.20011500. View

Pardieu C, Vigan R, Wilson S, Calvi A, Zang T, Bieniasz P . The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. PLoS Pathog. 2010; 6(4):e1000843. PMC: 2855335. DOI: 10.1371/journal.ppat.1000843. View

10.

Miyagi E, Andrew A, Kao S, Strebel K . Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc Natl Acad Sci U S A. 2009; 106(8):2868-73. PMC: 2650357. DOI: 10.1073/pnas.0813223106. View

11.

Sakuma T, Noda T, Urata S, Kawaoka Y, Yasuda J . Inhibition of Lassa and Marburg virus production by tetherin. J Virol. 2008; 83(5):2382-5. PMC: 2643706. DOI: 10.1128/JVI.01607-08. View

12.

Hammonds J, Wang J, Yi H, Spearman P . Immunoelectron microscopic evidence for Tetherin/BST2 as the physical bridge between HIV-1 virions and the plasma membrane. PLoS Pathog. 2010; 6(2):e1000749. PMC: 2816691. DOI: 10.1371/journal.ppat.1000749. View

13.

Kupzig S, Korolchuk V, Rollason R, Sugden A, Wilde A, Banting G . Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic. 2003; 4(10):694-709. DOI: 10.1034/j.1600-0854.2003.00129.x. View

14.

Van Damme N, Goff D, Katsura C, Jorgenson R, Mitchell R, Johnson M . The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe. 2008; 3(4):245-52. PMC: 2474773. DOI: 10.1016/j.chom.2008.03.001. View

15.

Goffinet C, Schmidt S, Kern C, Oberbremer L, Keppler O . Endogenous CD317/Tetherin limits replication of HIV-1 and murine leukemia virus in rodent cells and is resistant to antagonists from primate viruses. J Virol. 2010; 84(21):11374-84. PMC: 2953199. DOI: 10.1128/JVI.01067-10. View

16.

Hinz A, Miguet N, Natrajan G, Usami Y, Yamanaka H, Renesto P . Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin ectodomain. Cell Host Microbe. 2010; 7(4):314-323. PMC: 2859121. DOI: 10.1016/j.chom.2010.03.005. View

17.

Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, Fofana I . Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog. 2009; 5(5):e1000429. PMC: 2673686. DOI: 10.1371/journal.ppat.1000429. View

18.

Zhang F, Wilson S, Landford W, Virgen B, Gregory D, Johnson M . Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe. 2009; 6(1):54-67. PMC: 2852097. DOI: 10.1016/j.chom.2009.05.008. View

19.

Iwabu Y, Fujita H, Kinomoto M, Kaneko K, Ishizaka Y, Tanaka Y . HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. J Biol Chem. 2009; 284(50):35060-72. PMC: 2787367. DOI: 10.1074/jbc.M109.058305. View

20.

Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, Piguet V . HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog. 2009; 5(9):e1000574. PMC: 2729927. DOI: 10.1371/journal.ppat.1000574. View